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Molecular radiotherapy using 177Lu-DOTATATE is a most effective
treatment for somatostatin receptor–expressing neuroendocrine tu-
mors. Despite its frequent and successful use in the clinic, little or
no radiobiologic considerations are made at the time of treatment
planning or delivery. On positive uptake on octreotide-based PET/
SPECT imaging, treatment is usually administered as a standard
dose and number of cycles without adjustment for peptide uptake,
dosimetry, or radiobiologic and DNA damage effects in the tumor.
Here, we visualized and quantified the extent of DNA damage re-
sponse after 177Lu-DOTATATE therapy using SPECT imaging with
111In-anti-γH2AX-TAT. This work was a proof-of-principle study of
this in vivo noninvasive biodosimeter with β-emitting therapeutic
radiopharmaceuticals. Methods: Six cell lines were exposed to
external-beam radiotherapy (EBRT) or 177Lu-DOTATATE, after which
the number of γH2AX foci and the clonogenic survival were measured.
Mice bearing CA20948 somatostatin receptor–positive tumor xeno-
grafts were treated with 177Lu-DOTATATE or sham-treated and
coinjected with 111In-anti-γH2AX-TAT, 111In-IgG-TAT control, or
vehicle. Results: Clonogenic survival after external-beam radio-
therapy was cell-line–specific, indicating varying levels of intrin-
sic radiosensitivity. Regarding in vitro cell lines treated with
177Lu-DOTATATE, clonogenic survival decreased and γH2AX
foci increased for cells expressing high levels of somatostatin
receptor subtype 2. Ex vivo measurements revealed a partial
correlation between 177Lu-DOTATATE uptake and γH2AX focus
induction between different regions of CA20948 xenograft tumors,
suggesting that different parts of the tumor may react differentially
to 177Lu-DOTATATE irradiation. Conclusion: 111In-anti-γH2AX-TAT
allows monitoring of DNA damage after 177Lu-DOTATATE therapy
and reveals heterogeneous damage responses.
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Neuroendocrine tumors (NETs) comprise a heterogeneous
group of neoplasms derived from peptide- and amine-producing
cells of the neuroendocrine system. Despite their relatively low
incidence, NETs are a heterogeneous and complicated tumor fam-
ily and represent a significant clinical challenge requiring multi-
disciplinary care (1). Somatostatin receptor (subtype 2 or 5)
expression in most differentiated neuroendocrine cancers allows
treatment with somatostatin analogs such as octreotide, as well as
imaging and therapy with radiolabeled somatostatin analogs.
Compounds such as DOTATOC or DOTATATE are radiolabeled
with g-emitting radionuclides such as 111In for SPECT imaging,
positron emitters such as 68Ga for PET imaging, or the b-emitting
177Lu or 90Y for molecular radiotherapy (MRT). MRT with small
radiolabeled peptides, also called peptide receptor radionuclide
therapy, using these b-emitting radiopharmaceuticals is now used
routinely to treat NET patients (2). A large phase 3 study (the
NETTER trial) demonstrated that 177Lu-DOTATATE significantly
improved progression-free survival when compared with high-dose
octreotide in patients with advanced midgut NETs, with minimal
and transient side effects (3,4).
The radiobiologic aspects of 177Lu-DOTATATE, as for other
MRT radiopharmaceuticals, have been underexplored (5). Despite
its frequent and successful use, dosimetry is not always considered
at the time that peptide receptor radionuclide therapy is planned or
delivered. Little radiobiologic evaluation is performed (6,7), and
therapy outcome is not measured until late (3 mo) after treatment,
with no measurements of intratumoral heterogeneity, intracellu-
lar dosimetry, or short-term efficacy readouts. Although
177Lu-DOTATATE, 90Y-DOTATOC, and, increasingly, 177Lu-PSMA
(prostate-specific membrane antigen) are widely used throughout
Europe, therapy invariably consists of 2 or 4 intravenous admin-
istrations of 7.4 GBq, separated by 9–12 wk, mostly regardless of
the patient’s size and weight, the extent of positive 111In-octreotide
or 68Ga-DOTATATE uptake (measured by SPECT or PET imag-
ing, respectively), or the inherent radiosensitivity of the tumor or
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patient (8,9). Importantly, most MRT dosimetry and radiobiology
have been based on external-beam radiotherapy (EBRT) data be-
cause of a paucity of radiobiologic data on radionuclide therapy
(10). This substitution of EBRT for MRT dosimetry cannot ade-
quately account for the distinct and complex cellular localization
of ionizing radiation with MRT and the distinctly different dy-
namic biologic response across the time frame of exposure during
MRT. Although in vitro dosimetry methods exist, they require op-
timization for each cell line and are progressively complicated for
each cell line with in vitro 3-dimensional spheroid cellular constructs
(11). Even despite the best assessments of physical dose deposition,
the effect that matters most is radiation cytotoxicity, and different
cells, including cancer cells, react differently to the same absorbed
dose. Thus, a biologic dosimetry approach may be used by mea-
suring the extent of biologic response to ionizing radiation, such
as DNA damage repair signaling. This biodosimetry approach
can be considered a more direct measure of effective biologic
dose and may have greater translational potential in the clinic.
The major cytotoxic effect of MRT is mediated by causing DNA
damage. The b-decay of 177Lu-DOTATATE induces a variety of
DNA damage, including single-strand breaks, as well as DNA
double-strand break damage, one of the most lethal types of
DNA damage. One of the responses to DNA double-strand break
damage is phosphorylation of the histone isoform H2AX on ser-
ine-139 to form gH2AX. This phosphorylation is expressed in foci
of several thousand copies around the DNA double-strand break
site, where it acts as a scaffold to attract downstream DNA repair
factors. gH2AX repair foci have traditionally been used in radio-
biology to gauge the extent of DNA double-strand break damage
after ionizing radiation, such as EBRT.
Previously, we have developed a radiolabeled modified version
of an anti-gH2AX antibody, 111In-anti-gH2AX-TAT, that allows
us to noninvasively visualize and quantify gH2AX expression in
tumor tissue as a surrogate imaging-based measure of the extent of
DNA double-strand break damage. The radiolabeled full-length
antibody is modified with the TAT peptide, a cell-penetrating peptide
that incorporates a nuclear localization sequence to enable the anti-
body to enter cells, penetrate the nucleus, and access its exclusively
intranuclear target, gH2AX (12). We showed that 111In-anti-
gH2AX-TAT, using SPECT imaging, enables measurement of
DNA damage in several scenarios: after EBRT (13–15); after EBRT
plus a radiosensitizer, such as an ATR inhibitor (16); after chemo-
therapies such as bleomycin, 5-FU, gemcitabine, or capecitabine in
mouse models of breast or pancreatic cancer (13,17); and after DNA
damage repair hyperactivation during tumorigenesis in a mouse
model of HER2-driven breast cancer (12,13,18). In addition, we
reported on a 89Zr-labeled version for PET imaging of gH2AX (15).
Apart from b-particles, 177Lu emits g-rays (113 and 208 keV)
that can be used for SPECT imaging. These can be applied to
determine the accumulation of 177Lu in tissue and calculate the
absorbed radiation dose. The g-emissions of 111In do not overlap
with 177Lu (171 and 245 keV), allowing dual-isotope imaging to
simultaneously assess the physical dose distribution of 177Lu, as
well as its biologic effect on DNA damage repair signaling, with
111In-anti-gH2AX-TAT. This method may therefore allow adap-
tive clinical treatment regimens.
Here, we demonstrate that 177Lu-DOTATATE therapy results in
the formation of gH2AX foci in a mouse model of neuroendocrine
cancer, allowing us to gauge the extent of DNA damage using the
in vivo biodosimeter, 111In-anti-gH2AX-TAT, with dual-isotope
SPECT imaging of 177Lu and 111In.
MATERIALS AND METHODS
Full materials and methods are presented in the supplemental mate-
rials accompanying this article (supplemental materials are available
at http://jnm.snmjournals.org) (19–24).
General
177Lu-DOTATATE was prepared using previously described meth-
ods (25). Carrier-free 177Lu was obtained from ITG, and DOTATATE
precursor was obtained from Cambridge Biosciences. 177Lu-DOTATATE
was prepared to a molar activity of 50 MBq/nmol for in vitro use
and 86 MBq/nmol (60 MBq/mg) for in vivo experiments, unless
otherwise stated. The radiolabeling yield was routinely greater
than 99.5%, as determined by instant thin-layer chromatography.
Immunoconjugate was prepared and 111In-anti-gH2AX-TAT and 111In-
IgG-TAT radiosynthesized using mouse monoclonal anti-gH2AX
antibodies (clone JBW-301; Merck) or isotype-matched mouse non-
specific antibodies, as previously described (13).
Cells, Cell Uptake, and Fractionation
Cell membrane association, internalization, and nuclear localization
of 177Lu-DOTATATE were studied in the CA20948, BON1, QGP1,
H727, U2OS, and U2OSSSTR2 cell lines. We used the rat pancreatic
cancer cell line CA20948 for most of the work described here, in-
cluding in vivo studies, since it is one of only a handful of pancreatic
cancer models described in the literature that mimic the somatostatin
overexpression found in many human NETs and form tumors in vivo.
The cell line was derived from a rat pancreas and is acinar in origin yet
displays a neuroendocrine phenotype. Cells were harvested using
Accutase (Biolegend). Aliquots of 2 · 105 cells in 200 mL of growth
medium were exposed to 177Lu-DOTATATE (2.5 MBq/mL, 50 MBq/
nmol) for increasing durations at 37C for up to 24 h. The amount of
177Lu associated with cell membrane, cytoplasm, and nucleus was
then measured using an automated g-counter after cell fractionation
as previously described (26).
Clonogenic Survival
Cell suspensions (0.2 · 105 cells) were prepared using Accutase,
resuspended in growth medium (200 mL), and either treated with ra-
diolabeled 177Lu-DOTATATE (0–2.5 MBq/mL, 50 MBq/nmol) and
incubated at 37C for 2 h, or exposed to external g-irradiation (0–
10 Gy, 1 Gy/min, using a 137Cs irradiator), or sham-treated. An aliquot
of cells for each treatment condition was plated in 6-well plates with 2
mL of growth medium and incubated at 37C in 5% CO2. After 2 wk,
the number of colonies with more than 50 cells was counted to de-
termine the clonogenic survival fraction. Geometries derived from
confocal microscopy measurements of the dimensions of all cells in
the panel allowed the calculation of S values, which were used for
microdosimetry of 177Lu. The total absorbed radiation dose from
177Lu to cell nuclei was determined using a MIRD-based approach,
assuming homogeneous 177Lu uptake on membrane, in cytoplasm, and
in the nucleus. The total dose was calculated as the sum of self-dose
and cross-dose.
γH2AX Imaging by Confocal Microscopy
Cells were grown in 8-well culture chambers. After exposure of
cells either to 177Lu-DOTATATE (2.5 MBq/mL, 50 MBq/nmol) for 2 h
or to external-beam irradiation (6 Gy), they were left to recover in
fresh growth medium for 1, 24, 48, or 72 h. Cells were then washed,
fixed, permeabilized, and stained using a mouse anti-gH2AX antibody
(clone JBW-301, 1:800).
In Vivo Imaging
All animal procedures were performed in accordance with the
U.K. Animals (Scientific Procedures) Act of 1986 and with local
ethical committee approval. Female athymic nude mice were housed
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in individually ventilated cages in groups of up to 5 per cage in a
facility with an artificial day–night cycle and ad libitum access to food
and water. Tumor xenografts were generated by subcutaneous injec-
tion of cell suspensions (106 cells in 100 mL of serum-free growth
medium) in the right hind flank. Static SPECT/CT images were ac-
quired at 1, 24, 48, and 72 h after an intravenous bolus administration
of 177Lu-DOTATATE (20 MBq, 0.33 mg, in 100 mL of phosphate-
buffered saline). In a separate study, immediately after the 1-h SPECT
image the mice were additionally administered an intravenous bolus
of 111In-anti-gH2AX-TAT, 111In-IgG-TAT (5 MBq, 5 mg, in 100 mL of
phosphate-buffered saline), or phosphate-buffered saline control (Sup-
plemental Fig. 1). The average tumor size at the start of the study was
177 6 101 mm3. The average weight of the animals was 18 6 1.1 g.
SPECT/CT images were acquired in list mode for approximately
10 min using a single-gantry SPECT/CT and PET/CT scanner
(VECTor4CT; MILabs) equipped with a high-energy ultra-high-resolution
rat and mouse collimator containing pinhole apertures of 1.8-mm
diameter. Reconstructed images were viewed and analyzed using
PMOD (version 3.38; PMOD Technologies). Five animals were used
per group. After the final imaging session, the animals were culled,
and blood and selected tissues were harvested. 177Lu quantification
on SPECT images was based on an analysis of a series of standards
with known activity. Dual-isotope image reconstruction and quanti-
fication was performed using a series of phantoms containing a
range of 111In:177Lu mixtures (Supplemental Fig. 2). Digital autora-
diography and immunofluorescence confocal microscopy staining
for gH2AX was performed on 10-mm tumor sections. U2OS or
U2OSsstr2 cells did not form xenografts in BALB/c nu/nu mice in
our hands. The absorbed radiation dose from 177Lu was calculated
as previously described, based on volume-of-interest–derived vol-
ume measurements (3). The absorbed dose and absorbed dose rates
were calculated at each time point using the sphere model features
in the IDAC-Dose2.1 code for lymphoid tissue at a 1.03 g/mL
density.
Statistical Analysis
All statistical and regression analyses were performed using Prism
(version 7; GraphPad Software). Linear regression with runs testing
was used to check for correlations between measurements. After
testing for normality using a Shapiro–Wilk test, means were compared
using a t test with Welch correction for nonequal variances, when
applicable. One-way ANOVA followed by Dunnet posttesting was
used to compare multiple groups. Two-way ANOVA was used to
analyze grouped data. All results are reported as the mean 6 SD for
at least 3 independent replicates.
RESULTS
177Lu-DOTATATE Exposure and EBRT Cause Differential
Effects in a Set of Cell Lines In Vitro
Clonogenic survival after EBRT (0–10 Gy) in a panel of 6 cell
lines revealed that all 6 lines present with inherently distinct ra-
diation sensitivities (Fig. 1; Supplemental Fig. 3; Supplemental
Table 1), apart from the U2OS/U2OSsstr2 pair, for which trans-
fection of somatostatin receptor subtype 2 has no significant effect
on clonogenic survival (P . 0.05). D90 values (the absorbed
radiation dose at which clonogenic survival has dropped 10-fold)
are 5.3, 5.4, 5.5, 5.7, 8.0, and 9.5 Gy for U2OS, U2OSsstr2, BON1,
CA20984, H727, and QGP1 cells, respectively, indicating that the
various cells have varying levels of sensitivity to EBRT.
Uptake of 177Lu-DOTATATE in a panel of 6 cancer cell lines in
vitro occurred in line with expression of somatostatin receptor
subtype 2 and resulted in reduced clonogenic survival in cell lines
expressing somatostatin (Figs. 1–2; Supplemental Fig. 4). Transfection
of somatostatin-negative U2OS cells to stably express somatostatin
receptor subtype 2 receptors resulted in a 40-fold increase in cell-
associated 177Lu after 2 h of exposure to 177Lu-DOTATATE (6.2 6
1.7 vs. 250 6 1.6 mBq/cell; P , 0.0001) (Supplemental Fig. 4).
CA20948 cells, which naturally express high levels of somato-
statin receptor subtype 2, when exposed to 177Lu-DOTATATE took
up 177Lu (57 6 5.0 mBq/cell), in contrast to QGP1, BON1, or
H727 cells, which all express low levels of somatostatin recep-
tors (8.9 6 2.3, 6.2 6 5.4, and 8.4 6 1.1 mBq/cell, respec-
tively). Not surprisingly, clonogenic survival was reduced
significantly only in cells that express somatostatin and thus take
up 177Lu-DOTATATE.
The amount of 177Lu associated with the membrane, cytoplasm,
and nucleus of all cells at various times after exposure to 177Lu-
DOTATATE (Supplemental Fig. 4) was determined from cellular
fractionation. Although most cell-associated 177Lu was associated
with the membrane at all time points, a significant amount was
associated with the cytoplasmic fraction (13% in CA20948 cells at
2 h) but very little in the nucleus (,0.1%). Differences from
previously reported results may be explained by the fact that,
here, we performed the measurements not on adherent cells but
on cells in suspension. Given the range of b-particles emitted by
177Lu (on average, 1.7 mm), this method results in a radiation
dose to the cells and their nuclei, resulting in reduced clonogenic
survival.
FIGURE 1. Clonogenic survival after in vitro exposure of cancer cell lines to varying amounts of 177Lu-DOTATATE or increasing amounts of EBRT:
CA20948 cells (A), U2OSsstr2 cells (B), and wild-type U2OS cells (C). Absorbed radiation doses for 177Lu were based on 177Lu uptake data obtained
separately (Supplemental Fig. 4).
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Within these monoclonal cell cultures, clonogenic survival of
cells after exposure to 177Lu-DOTATATE correlated well with
absorbed dose (Fig. 1). However, comparing CA20948 and U2OSsstr2
cells, the same absorbed radiation dose from 177Lu-DOTATATE
resulted in clonogenic survival different from that after EBRT. Clo-
nogenic survival in CA20948 cells was higher for EBRT than for
the same radiation dose of 177Lu-DOTATATE (P , 0.0001),
whereas in U2OSsstr2 cells it was lower (P, 0.0001) (Supplemental
Table 1). This finding reinforces previous reports that the same dose
of EBRT and MRT does not result in the same biologic effect and
that this difference may vary among cell lines (27).
177Lu-DOTATATE Exposure in Somatostatin-Positive
Cells Results in γH2AX Foci In Vitro
Exposure of all cells to EBRT led to formation of gH2AX foci,
to different extents in each cell type (Fig. 2A). In CA20498 cells,
exposure to 177Lu-DOTATATE for 2 h also resulted in DNA dou-
ble-strand break damage, as measured by gH2AX foci (Figs. 2B
and 2C). Interestingly, the number of gH2AX foci per cell con-
tinued to increase significantly for up to 72 h after exposure to
177Lu-DOTATATE (42 6 14 vs. 15 6 9.7 in treated vs. nontreated
cells; P , 0.0001). This finding was in stark contrast to the num-
ber of gH2AX foci for a single dose of EBRT, after which
gH2AX foci were high shortly after irradiation (67 6 18; P ,
0.0001) but soon returned to pretreatment levels (13 6 6.1; P .
0.05 at 72 h), as is expected in most cells without DNA damage
repair defects.
A similar result was obtained in U2OSsstr2 cells, although here
the number of gH2AX foci did not increase at 72 h after exposure
to 177Lu-DOTATATE but at all times was higher than the number
in wild-type U2OS cells (P, 0.0001; Supplemental Fig. 5). These
results agree with earlier results from Dalm et al., who showed the
formation of another type of DNA damage repair foci, 53BP1 foci,
after 177Lu-DOTATATE treatment of U2OSsstr2 cells (28,29).
Thus, DNA damage repair signaling as
measured by gH2AX foci after exposure to
177Lu-DOTATATE is distinct from that after
EBRT.
177Lu-DOTATATE Uptake in Xenograft
Tumors Induces γH2AX Foci In Vivo
Intravenous administration of 177Lu-
DOTATATE to CA20948 xenograft–bearing
mice resulted in high tumor uptake (36 6
4.5 percentage injected dose [%ID]/mL at
24 h after administration; Fig. 3A), whereas
other xenografts took up far less 177Lu-
DOTATATE (P , 0.0001), in line with in
vitro results and somatostatin expression
levels (Supplemental Fig. 6A). Dynamic
SPECT imaging revealed that maximum
tumor uptake in CA20948 xenografts was
reached at 60 min after administration (Sup-
plemental Fig. 6B).
Comparable to our in vitro results, high
177Lu-DOTATATE uptake and gH2AX fo-
cus formation was observed in CA20948
xenografts 72 h after administration of
177Lu-DOTATATE (Figs. 3B–3F), com-
pared with nontreated tumors (Fig. 3G).
The delivery of 177Lu-DOTATATE to the
tumors was heterogeneously distributed, as has been observed
previously (30). A comparison of autoradiography showing 177Lu
uptake in a tumor section with immunohistochemistry staining for
gH2AX revealed that, in general, areas of tumor with higher 177Lu
uptake showed a higher number of gH2AX foci per cell (Fig. 3E)
and areas with lower 177Lu uptake showed fewer gH2AX foci per
cell (Fig. 3F), but this correlation was not linear or significant. Only
a few cells with pan-nuclear staining, indicating late-stage apopto-
sis, were observed. Interestingly, a large number of regions with
intermediate 177Lu uptake could also be observed, with the num-
ber of gH2AX foci being highly variable. A correlation plot
quantitatively comparing the 2 signals revealed a similar lack of
pattern (Fig. 3D). Similar observations were made for all tumors (3
additional examples are shown in Supplemental Fig. 7), indicating
that yH2AX may be used as a marker for the biologic effect of
177Lu therapy.
111In-Anti-γH2AX-TAT Allows In Vivo Imaging of DNA
Damage After 177Lu-DOTATATE Therapy
111In-anti-gH2AX-TAT enabled imaging of gH2AX in vivo.
Dual-isotope imaging of 177Lu-DOTATATE and 111In-anti-gH2AX-
TAT allowed concurrent imaging of tumor-associated 177Lu and
visualization of the DNA double-strand break damage resulting
from the emitted b-particles. The ability of the VECTor4 imaging
system to simultaneously acquire images for 111In and 177Lu was
evaluated using phantoms containing mixtures of known amounts of
either radionuclide. Samples containing only 177Lu did not show
any signal in the reconstructed 111In image, and vice versa. Impor-
tantly, quantification of 111In or 177Lu was not influenced by the
presence of the other isotope (R 5 0.99, P , 0.0001; Supplemental
Fig. 2), corroborating earlier reports on dual-isotope imaging with
this system (31,32).
111In-anti-gH2AX-TAT uptake increased in tumors treated with
177Lu-DOTATATE. Volume-of-interest analysis of the 111In signal
FIGURE 2. γH2AX focus formation in panel of cell lines. (A) Cells were stained for γH2AX (green)
and somatostatin receptor subtype 2 (red) 1 h after exposure to 4 Gy of EBRT. 4′,6-diamidino-2-
phenylindole (DAPI) was used to stain cell nuclei (blue) (scale bar 5 50 μm). (B) Number of γH2AX
foci per cell was determined at various intervals after exposure of CA20948 cells to 177Lu-DOTATATE
for 2 h or after EBRT (6 Gy). *P , 0.01. ***P , 0.0001. (C) Representative immunocytochemistry
micrographs (γH2AX 5 green, nuclei 5 blue) (scale bar 5 10 μm).
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in SPECT/CT images acquired at various time points revealed a
significant increase in tumor uptake of 111In-anti-gH2AX-TAT in
CA20948 tumor xenografts 72 h after injection (73 h after intrave-
nous administration of 20 MBq of 177Lu-DOTATATE), as com-
pared with 111In-anti-gH2AX-TAT uptake in control animals
(P 5 0.0033) or uptake of the nonspecific control compound, 111In-
IgG-TAT, with or without 177Lu treatment (P , 0.0001) (Figs. 4
and 5). Uptake of the nonspecific control compound, 111In-IgG-TAT,
was not altered by treatment of the tumors with 177Lu-DOTATATE
(P 5 0.41), confirming that the effect on 111In-anti-gH2AX-TAT is
not due to physiologic changes that may affect nonspecific uptake of
the IgG-TAT construct. Detailed data on the tumor uptake in each
mouse are reported in Supplemental Figure 8. In addition, we
observed no significant differences on the uptake of 177Lu in tu-
mors or any normal tissues after administration of 111In-anti-
gH2AX-TAT compared with 111In-IgG-TAT (P . 0.05) (Fig.
4B; Supplemental Fig. 9). In vivo tumor uptake of 111In-anti-
gH2AX-TAT followed the same trend over 72 h as the number
of gH2AX foci in vitro after brief exposure to 177Lu-DOTATATE.
No statistically significant differences in uptake of 111In-anti-
gH2AX-TAT or 111In-IgG-TAT were observed in any organ
of mice exposed to 177Lu-DOTATATE versus untreated animals
(P . 0.05), with the exception of the spleen (P 5 0.0009) (Sup-
plemental Fig. 9). Given the very low uptake of 177Lu in the mouse
spleen (0.43 6 0.23 %ID/g at 72 h), radiation exposure seems an
unlikely source in mice, although in humans the spleen receives a
nonnegligible dose after 177Lu-DOTATATE (4.5–15 Gy over 2–5
cycles) (33). Notably, in our experimental setup, we observed no
differences in uptake of 111In-anti-gH2AX-TAT in mouse kidney,
the tissue that is the most exposed to 177Lu radiation, second only
to tumor.
Volume-of-interest analysis of the 177Lu signal in all images
allowed us to calculate the average absorbed radiation dose to
the tumor in 177Lu-DOTATATE–treated animals as 12.9 6 3.4
Gy (after 72 h; Supplemental Table 2; Supplemental Fig. 10),
similar to previously reported values (29). Clearance from the
tumor xenografts occurred with a mean effective half-life of 46.36
8.6 h. There was no statistical difference in the average absorbed
dose from 177Lu between animals imaged with 111In-anti-gH2AX-
TAT and animals imaged with 111In-IgG-TAT (P 5 0.15, Mann–
Whitney test). Contrary to our earlier observations after EBRT (13),
the accumulated absorbed dose from 177Lu, and the dose rate of
177Lu at any given time, did not correlate with 111In-anti-gH2AX-
TAT uptake in the tumor, at least not in the limited dataset analyzed
here (P . 0.55, n 5 5).
111In-Anti-γH2AX-TAT Shows Heterogeneity In Vivo
Pixel-by-pixel segmentation of tumor volumes, based on the
magnitude of the 177Lu signal, allowed correlation with the
FIGURE 4. (A) Tumor uptake of 111In-anti-γH2AX-TAT or 111In-IgG-TAT
at various times after treatment of CA20948-bearing mice with 177Lu-
DOTATATE (20 MBq, 0.33 μg) or vehicle control. **P, 0.005. (B) Uptake
of 177Lu in tumor of 177Lu-DOTATATE–treated animals.
FIGURE 3. (A) Representative SPECT/CT image 72 h after intravenous administration of 177Lu-DOTATATE (20 MBq, 0.33 μg) in CA20948 xeno-
graft–bearing athymic mouse. (B) Autoradiography (AR) performed on tumor section harvested from same mouse. (C) Adjacent section was stained
for γH2AX, and resulting fluorescence micrograph was coregistered to AR image (scale bar 5 800 μm) (D) Density scatterplot based on pixel-by-
pixel analysis of γH2AX signal vs. autoradiography (omitting edge effects on immunohistochemistry). (E and F) High-resolution details of immuno-
histochemistry in C, demonstrating γH2AX foci in areas of intense or minimal staining (γH2AX 5 green; nuclei 5 blue; scale bar 5 20 μm). (G)
Immunohistochemistry for γH2AX on representative tumor section from mouse that was treated with vehicle control only.
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amount of 111In signal in various substructures within the tumor
(Fig. 5). Consistent with our earlier ex vivo gH2AX focus mea-
surements (Fig. 3), qualitative analysis revealed that, in general,
areas within the tumor with higher 177Lu uptake also took up more
111In-anti-gH2AX-TAT at all time points, a correlation that was
linear up to approximately 20 %ID/g of 177Lu (R2 5 0.9843, P ,
0.0001, Fig. 5B), but the same was not true for 111In-IgG-TAT
(Fig. 5D). However, consistent with our earlier ex vivo gH2AX
focus measurements (Fig. 3), our results hint toward a more com-
plex relationship between 177Lu uptake and the radiobiologic re-
sponse, especially at the higher end of 177Lu exposure, than would
be suggested by a 177Lu-radiation–deposited dose alone.
DISCUSSION
Here we show, for the first time to our knowledge, that the DNA
double-strand break damage marker gH2AX, as induced by MRT
with 177Lu, can be visualized and quantified noninvasively by
whole-body molecular imaging. First, we confirmed that exposure
of somatostatin-expressing cells to 177Lu-DOTATATE in vitro
resulted in reduced clonogenic survival. Different cell lines
responded differently to the same absorbed 177Lu dose. The same
was true for EBRT. Nonetheless, sensitivity to EBRT did not
correlate linearly with sensitivity to 177Lu. DNA double-strand
break damage was observed in vitro by immunofluorescence, as
measured by gH2AX foci. The kinetics of
gH2AX formation and dissolution after
177Lu exposure was different from that
after EBRT. It has been shown previously
that the therapeutic success of ionizing
radiation correlates closely with the induc-
tion of DNA double-strand break damage,
especially with late, unrepaired dam-
age (34). 177Lu-DOTATATE causes DNA
damage in vivo in tumor tissue and thus
causes expression of gH2AX. We demon-
strated that this induction of gH2AX after
177Lu-DOTATATE therapy can be monitored
by SPECT imaging with 111In-anti-gH2AX-
TAT. We were able to simultaneously study,
in the whole tumor, the relationship between
177Lu distribution, as a surrogate for absorbed
dose, and one aspect of the radiobiologic re-
sponse of the tumor, DNA double-strand
break damage repair, as measured by gH2AX
expression. On average over the whole tumor,
111In-anti-gH2AX-TAT uptake is in-
creased after 177Lu-DOTATATE therapy
over 72 h, similar to our in vitro immuno-
fluorescence results. Most interesting, how-
ever, is that within each tumor, the amount
of DNA damage as measured by gH2AX
foci does not strictly correlate with the
amount of 177Lu deposition within tumors
(Figs. 3 and 5). This finding suggests a
more complex relationship between the
amount of 177Lu uptake and the macro-
scopic radiation dose deposited in various
parts of the tumor, with the resulting bi-
ologic effects such as DNA damage repair.
This proof-of-principle study showed
that DNA damage from MRT can be measured noninvasively and
may potentially be used as an in vivo biodosimeter. To the best of
our knowledge, this was the first study of its kind—one that mea-
sures the direct, mechanistic, biologic effects of MRT. Understand-
ably, some challenges need to be overcome before translation to the
clinic is possible. Our initial results here were obtained using
athymic mice bearing rat xenografts, but the results can be readily
extrapolated to the human situation, given that similar interplay
exists between 177Lu uptake, heterogeneous 177Lu tumor uptake,
and DNA damage and repair. Without underestimating the impor-
tance of the physical radiation dose deposited in tumor and normal
tissue for all MRT agents, the radiobiologic effects of MRT need to
be considered when predicting therapeutic outcome. Different tu-
mors react differently to EBRT, as demonstrated in the limited panel
of 6 tumor cell lines. The cell line panel used here also portrayed
differences in gH2AX kinetics after EBRT, given their inherent
differences in radiosensitivity and potential further dissimilarities
in cell signaling due to mutations, epigenetic or posttranslational
variations in DNA damage repair proteins, and differential stress
responses. Therefore, the same must be true for MRT. In addition,
MRT effects will be complicated by the combination of receptor
expression level, radionuclide uptake, radionuclide deposited dose,
intratumoral heterogeneity (11), subcellular distribution (35), and
radiobiologic effects, as well as tumor microenvironmental parame-
ters such as hypoxia and systemwide effects such as immune-system
FIGURE 5. (A) Representative dual-isotope SPECT/CT images of mice 71 h after intravenous
administration of 111In-anti-γH2AX-TAT (5 MBq, 5 μg) and 72 h after intravenous administration of
177Lu-DOTATATE (20 MBq, 0.33 μg). Tumor is indicated by purple contour in 177Lu image. (B)
Correlation between 111In and 177Lu signal in tumor volume in voxel collections based on 177Lu signal
quantification in SPECT image of animal in A. (C) Representative dual-isotope SPECT/CT images of
mice after administration of 111In-IgG-TAT (5 MBq, 5 μg) and 177Lu-DOTATATE (20 MBq, 0.33 μg).
Tumor is indicated by purple contour in 177Lu image. (D) Correlation between 111In and 177Lu signal in
tumor volume in voxel collections based on 177Lu signal quantification in SPECT image of animal in C.
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effects. Here, we have not considered the effects of those systemwide
consequences. As used here, 111In-anti-gH2AX-TAT provides one
potential biodosimeter to establish a measurement of the radio-
biologic effects of MRT with 177Lu-DOTATATE. Its clinical ap-
plicability is yet to be tested. It is worth noting that gH2AX, and
therefore imaging with 111In-anti-gH2AX-TAT, remains a sec-
ondary biomarker, and gH2AX can also be upregulated as a re-
sult of some other cellular stress responses, such as oncogenic
stress, increased genomic instability, and late-stage apoptosis
(18,36). Therefore, 111In-anti-gH2AX-TAT imaging may not reflect
DNA double-strand break damage only. The most likely alterna-
tive cause of gH2AX upregulation is MRT-induced apoptosis,
resulting in pan-nuclear gH2AX staining. However, we did not
observe this in the time span during which we imaged gH2AX
here, making 111In-anti-gH2AX-TAT a suitable agent for imag-
ing the early DNA damage response.
In this work, we showed imaging of DNA damage after 177Lu
therapy based on a DOTATATE vector. However, the same system
can be used to evaluate other MRT agents, such as 177Lu-PSMA,
which is increasingly applied for the treatment of prostate cancer,
long-range b-emitting radiopharmaceuticals based on 90Y or 131I,
or targeted a-emitter therapy based on 225Ac or 231Bi, given their
propensity to cause complex DNA damage and abundant gH2AX
signals (37). gH2AX has also been suggested as a biomarker of
normal-tissue toxicity, such as renal toxicity after MRT (38), and a
marker of peripheral blood lymphocyte toxicity (39). However, we
did not observe any significant changes in renal uptake of 111In-
anti-gH2AX-TAT, likely because the amount of 177Lu-DOTA-
TATE used in our studies did not cause clinically significant renal
damage or because the physiologic renal uptake of 111In-anti-
gH2AX-TAT (5.1 6 0.4 %ID/g at 72 h after administration in
animals not exposed to 177Lu-DOTATATE) prevents observation
of these differences.
Agents that image response to therapy, such as 111In-anti-
gH2AX-TAT or its PET alternative, 89Zr-anti-gH2AX-TAT (15),
might find applications in adaptive therapy. Similar to measuring
the genotoxic effects of chemotherapy (17), EBRT (13), and radio-
sensitizers (16), measuring the effects of radionuclide therapy in
vivo may allow adjustment of the therapeutic regimen in accor-
dance with the individual patient’s response to that treatment. In
addition, noninvasive imaging can reveal differential responses in
multiple tumors in the same patient or elucidate the heterogeneous
biologic response within the same tumor. Using therapeutic re-
sponse assessment with molecular imaging, making rapid decisions
becomes possible, rather than having to await the anatomic changes
that potentially follow later, after successful therapy. It is notable,
however, that metabolic responses to some of the latest targeted
therapies are not necessarily accompanied by an anatomically ob-
vious response (40). Such stratification, possible after a single cycle
of MRT, allows for an adaptive treatment design (5), a dose reduction
to avoid side effects, assessment of combination therapies, or, in the
absence of any measurable response, initiation of palliative options
designed toward improving quality of life. Moreover, this strategy
may also be a financially prudent one, given the high cost of each
dose of Lutathera ($47,500; Advanced Accelerator Applications).
CONCLUSION
Imaging of the DNA damage response using 111In-anti-gH2AX-TAT
provides unique insight after 177Lu-DOTATATE therapy and al-
lows the visualization of biologic response. This includes not
only intratumoral heterogeneity but also interlesion heterogene-
ity within the same patient.
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KEY POINTS
QUESTION: Can the radiolabeled antibody 111In-anti-γH2AX-
TAT be used in vivo to visualize and quantify the γH2AX foci
generated at the sites of double-strand DNA breaks caused by
177Lu-DOTATATE therapy?
PERTINENT FINDINGS: The γH2AX foci induced by 177Lu-
DOTATATE could be imaged by SPECT in vivo using 111In-anti-
γH2AX-TAT, and they correlated with ex vivo and in vitro γH2AX
levels. γH2AX expression revealed intratumoral and interlesion
heterogeneity with the absorbed 177Lu dose, suggesting a com-
plex biologic response to 177Lu therapy.
IMPLICATIONS FOR PATIENT CARE: 111In-anti-γH2AX-TAT can
potentially be used as a biodosimeter for optimizing radionuclide
treatments such as 177Lu-DOTATATE, both in preclinical investi-
gations and in the design of personalized, adaptive treatment
regimens for patients.
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